Metastatic Colon Cancer
Conditions
Brief summary
Colon cancer is one of the most common cancers in France with more than 36,000 new cases per year. Despite significant advances in therapeutic care, the prognosis of colon cancers with metastases remains bad. The treatment of metastatic disease is based on chemotherapy coupled with therapeutic antibodies. The most commonly used are anti-EGFR (Epidermal Growth Factor Receptor), which allowed a significant increase in patient survival. They are responsible for skin toxicity in the form of an acneiform rash which can be debilitating for patients and require discontinuation of treatment. However, this toxicity is strongly correlated with treatment efficacy. Understanding the mechanisms of cutaneous side effects of anti-EGFR is therefore a major challenge to treat and better understand the association with treatment efficacy. The objective of this study is to investigate a link between cutaneous inflammatory response in patients treated with anti-EGFR, serum level of anti-EGFR and treatment efficacy. It will be conducted systematic consultations dermatology, skin biopsies and blood samples in patients treated with anti-EGFR. From biopsies, it will be searched by an infiltration of inflammatory cells and expression of genes involved in skin inflammation.
Interventions
DRUGcetuximab
Sponsors
Poitiers University Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients older than 18 years * Patient with histologically proven metastatic colorectal cancer with KRAS wild-type * Treatment with cetuximab in first line chemotherapy combined with FOLFOX or FOLFIRI * Patient has signed informed consent * Patient affiliated to the Social Security * Prescription of cetuximab in agreement with the Summary of Product Characteristics
Exclusion criteria
* Patients aged under 18 * Patients taking immunosuppressive therapy * Patient having a severe skin disease * No measurable metastasis * Patients with a contra-indication of cetuximab: hypersensitivity to cetuximab or to any excipients * Severe alteration of respiratory or cardiac function or severe coronary disease * Patients with contra-indication to chemotherapy FOLFOX and FOLFIRI * Participation in another research protocol * Patients not affiliated to the Social Security * Hospitalized patients without consent * Pregnant or nursing women, women of childbearing age with no effective contraception
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main criteria is the variation of skin pro-inflammatory cytokines in pre and post-therapeutic punch skin biopsies | — |
Countries
France
Outcome results
None listed